Article Text

PDF
Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy
  1. M Saraste1,
  2. J Ryynänen1,
  3. A Alanen2,
  4. J Multanen3,
  5. M Färkkilä3,
  6. R Kaaja4,
  7. L Airas5
  1. 1MediCity Research Laboratory, University of Turku, Turku, Finland
  2. 2Department of Gynecology and Obstetrics, University of Turku
  3. 3Department of Neurology, University of Helsinki, Helsinki, Finland
  4. 4Department of Gynecology and Obstetrics, University of Helsinki
  5. 5MediCity Research Laboratory, Department of Neurology, University of Turku
  1. Correspondence to:
 Dr Laura Airas
 Department of Neurology, University of Turku, PO Box 52, 20521 Turku, Finland; laura.airas{at}utu.fi

Statistics from Altmetric.com

The mechanisms responsible for the lower relapse rate of multiple sclerosis during pregnancy and an increased relapse rate during the postpartum period are still undefined. Putative explanations include pregnancy-related alterations in the function of the immune system, such as a shift towards T helper (Th)2-type immune reactivity and expansion of regulatory T lymphocytes.1,2 Analysis of the cerebrospinal fluid (CSF) offers a unique opportunity to characterise immunological pathways in the pathogenesis of multiple sclerosis. The inflammatory activity in the central nervous system (CNS) of patients with multiple sclerosis is reflected in the composition of CSF cells and one hallmark of the disease is the production of intrathecal antibodies. The aim of our study was to investigate the alterations that take place in the CSF of patients with multiple sclerosis during pregnancy. To our knowledge, no previous attempts have been made to analyse the components of the CSF of pregnant patients with multiple sclerosis.

METHODS

The study included six patients with relapsing remitting multiple sclerosis, who were enrolled at a time of known pregnancy status. Follow-up with recording of relapses continued until 6 months after the delivery. Only one of the patients (case 5) was undergoing disease-modifying treatment (subcutaneous interferon (IFN)β-1a) before pregnancy, and the drug was discontinued 3 months before the onset of pregnancy. No immunomodulatory …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.